Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1991-11-7
|
pubmed:abstractText |
The effects of a competitive, N-methyl-D-aspartate (NMDA) receptor antagonist, D(-)E-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid (D-CPPene), on the volume of ischemic brain damage was assessed by quantitative histological study in 35 chloralose-anesthetized cats. Focal cerebral ischemia was produced by permanent occlusion of one middle cerebral artery and the animals were killed by transcardiac perfusion fixation 6 hours later. Pretreatment with D-CPPene (1.5, 4.5, or 15 mg/kg, administered intravenously 15 minutes prior to occlusion, with subsequent drug infusions to maintain a plateau in the plasma drug concentrations) effected dose-dependent reductions in the volume of ischemic brain damage. At the highest dose studied (15 mg/kg, plus an infusion of 170 micrograms/kg/min), D-CPPene reduced the volume of ischemic damage in the cerebral cortex by more than 75% compared to vehicle-treated control animals. The plasma concentration of D-CPPene, which is associated with a half maximal reduction in the volume of ischemic damage, was estimated to be 24 micrograms/ml during the initial 120 minutes after the middle cerebral artery occlusion. Treatment with D-CPPene (15 mg/kg, plus an infusion of 170 micrograms/kg/min) initiated 1 hour after occlusion reduced the volume of ischemic brain damage in the cerebral cortex by 30%, but this response did not achieve statistical significance. Precise definition of dose dependency for the anti-ischemic effects of NMDA antagonists and the therapeutic time window are influenced greatly by brain pharmacokinetics of the agents.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dizocilpine Maleate,
http://linkedlifedata.com/resource/pubmed/chemical/N-Methylaspartate,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, N-Methyl-D-Aspartate,
http://linkedlifedata.com/resource/pubmed/chemical/SDZ EAA 494
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0364-5134
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
62-70
|
pubmed:dateRevised |
2009-9-29
|
pubmed:meshHeading |
pubmed-meshheading:1834008-Animals,
pubmed-meshheading:1834008-Binding, Competitive,
pubmed-meshheading:1834008-Brain,
pubmed-meshheading:1834008-Brain Ischemia,
pubmed-meshheading:1834008-Cats,
pubmed-meshheading:1834008-Caudate Nucleus,
pubmed-meshheading:1834008-Cerebral Cortex,
pubmed-meshheading:1834008-Dizocilpine Maleate,
pubmed-meshheading:1834008-Drug Administration Schedule,
pubmed-meshheading:1834008-Half-Life,
pubmed-meshheading:1834008-N-Methylaspartate,
pubmed-meshheading:1834008-Piperazines,
pubmed-meshheading:1834008-Receptors, N-Methyl-D-Aspartate
|
pubmed:year |
1991
|
pubmed:articleTitle |
Evaluation of a competitive NMDA antagonist (D-CPPene) in feline focal cerebral ischemia.
|
pubmed:affiliation |
Wellcome Neuroscience Group, University of Glasgow, United Kingdom.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|